NUVL Stock Recent News

Nuvalent, Inc. (NUVL) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

Does Nuvalent, Inc. (NUVL) have what it takes to be a top stock pick for momentum investors? Let's find out.

CAMBRIDGE, Mass. , Oct. 17, 2022 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that management will host a live webcast and conference call in conjunction with its data presentations at the 34th EORTC-NCI-AACR (ENA) Symposium in Barcelona, Spain on Friday, October 28, 2022 at 8:30 a.m.

Preliminary Dose Escalation Data on ROS1-selective Inhibitor NVL-520 to be Presented in the "New Drugs on the Horizon" Oral Plenary Session New Preclinical Data to be Presented on Parallel-lead, Clinical-stage Candidate NVL-655, an ALK-selective Inhibitor Selection of Third Development Candidate NVL-330, a Potential Best-in-Class HER2-selective Inhibitor for Patients with HER2 Exon 20 Insertion-Positive Cancers, and Preclinical Characterization to be Presented Company Plans to Host Conference Call in Conjunction with Data Presentation on October 28, 2022 CAMBRIDGE, Mass. , Sept. 7, 2022 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced it will present preliminary dose escalation data from its ongoing ARROS-1 Phase 1/2 clinical trial of NVL-520 for patients with advanced ROS1-positive non-small cell lung cancer (NSCLC) and other solid

CAMBRIDGE, Mass. , Aug. 3, 2022 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that James Porter, Ph.D.

Preclinical activity of ALK-selective inhibitor NVL-655 in a lorlatinib-resistant model of NSCLC with a compound resistance mutation continues to support potential for best-in-class profile CAMBRIDGE, Mass. , July 13, 2022 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced it will present two posters for its parallel lead programs, NVL-655, an ALK-selective inhibitor and NVL-520, a ROS1-selective inhibitor, at the IASLC 2022 World Conference on Lung Cancer (WCLC) Annual Meeting taking place August 6-9, 2022 in Vienna, Austria.

CAMBRIDGE, Mass. , June 2, 2022 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that James Porter, Ph.D.